Latest news with #nanoparticle
Yahoo
6 days ago
- Health
- Yahoo
POP BIO and CEPI announce collaboration for faster responses to Disease X
Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new collaboration to accelerate the development of vaccines against future pandemic threats, including a potential 'Disease X'. Backed by up to $1.5 million in funding from CEPI, the partnership will advance POP BIO's SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform—a plug-and-play technology designed to enable rapid-response vaccine development through streamlined protein purification and nanoparticle BIO announces collaboration with CEPI The expert team, based at the pharmaceutical start-up POP BIO, are being awarded up to US $1.5 million from CEPI to advance research into POP BIO's SNAP™ (Spontaneous Nanoliposome Antigen Particleization) protein vaccine platform. The technology has been designed to rapidly develop potent nanoparticle vaccine candidates, while simultaneously purifying antigens. Inert protein fragments of a disease-causing pathogen, known as antigens, are added to a vaccine to teach the body's immune system how to recognise and defend against it. 'Antigens added to vaccine formulations have to be purified to ensure safety, efficacy and consistency of the vaccine. However, conventional purification methods can be costly and involve multiple steps, typically lasting several days, slowing down the vaccine development process' said Dr. Kent Kester, Executive Director of Vaccine R&D at the Coalition for Epidemic Preparedness Innovations (CEPI). Through an innovative approach, the SNAP proprietary technology makes use of a small protein tag, termed a polyhistidine or his-tag, that is attached to the vaccine antigens—for a purification technique commonly used in basic protein research—and is also used to embed them into small, spherical liposomes combined with metallic cobalt to aid the immune response. Compared to traditional purification methods, the enhanced technique could rapidly remove potential contaminants from vaccine antigens in as little as 30 minutes. 'As every day counts during an incipient outbreak, faster development of purified vaccine constructs could help more quickly contain a fast-spreading new or re-emerging viral threat before it spreads to pandemic proportions, in line with the 100 Days Mission' says Dr. Kester. SNAP's versatile plug-and-play design could also be beneficial in an outbreak as the antigen sourced from the disease-causing pathogen could be easily and quickly "plugged' into the vaccine platform for faster development and deployment of vaccines. With fewer, less complex stages involved in its purification process, the SNAP technology could also be more efficient than traditional protein vaccine purification methods, producing higher antigen yields that help extend available vaccine supplies and allow more people to be vaccinated in an outbreak. 'The dual use of the his-tag to facilitate protein purification and to then easily, rapidly and stably convert those proteins into potent nanoparticle vaccine candidates has been instrumental for the momentum POP BIO has achieved,' says POP BIO co-founder Jonathan Lovell. 'Importantly, when the his-tag is used to anchor proteins on the surface SNAP nanoparticles, there is no significant immune response against the tag itself, as observed in human clinical testing.' The SNAP technology has already been tested through a large-scale, late-stage Phase III trial of SNAP's COVID-19 vaccine, where it demonstrated positive safety and efficacy results. Positive results were also published earlier this year in the journal Cell Biomaterials for an avian H5N1 influenza vaccine developed with POP BIO's SNAP platform in preclinical models. The CEPI-supported project will first explore the technology's potential to protect against severe fever with thrombocytopenia syndrome (SFTS), a tick-borne viral disease affecting East Asia, in preclinical trials. Led by POP BIO, the project will be performed by an international team of researchers at the University of Buffalo and SUNY Upstate Medical University in the US and The National Institute of Infectious Diseases, within the Japan Institute for Health Security. CEPI is exploring options to select antigens for testing from CEPI's existing partners, including our partners using AI to inform antigen design. If the project is successful, the SNAP platform has the potential to be rapidly adapted to develop vaccine candidates against other pathogens, including a Disease X. CEPI and POP BIO are committed to enabling equitable access to the outputs of their partnership, in line with CEPI's Equitable Access Policy. Project results, including related data, will be published open access for the benefit of the global scientific BIO staff scientists Dr. Hilliard Kutscher and Matthew Willadsen About POP Biotechnologies POP Biotechnologies, Inc. is a privately held biotechnology company developing novel therapeutics and vaccines based on its proprietary porphyrin-phospholipid (PoP) liposome technology. The PoP platform, exclusively licensed from the State University of New York Research Foundation (SUNY-RF), was invented by co-founder Dr. Jonathan Lovell at SUNY Buffalo. POP Biotechnologies operates from the SUNY Buffalo incubator at Baird Research Park. About POP BIO's SNAP™ Technology POP BIO's SNAP™ (Spontaneous Nanoliposome Antigen Particleization) enables therapid development of potent particle-based vaccines by leveraging a cobalt-modified PoP liposome system (CoPoP). This platform allows for stable, spontaneous liposome display of protein and peptide antigens, substantially enhancing immunogenicity. POP BIO's SNAP™ demonstrated favorable safety and immunogenicity profiles in Phase 3 trials of the EuCorVac-19 COVID-19 vaccine. About CEPI CEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic disease threats and enable equitable access to them. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens and is also advancing the development of rapid response platforms for vaccines against a future Disease X. Central to CEPI's pandemic-beating five-year plan for 2022-2026 is the '100 Days Mission' to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. Press Inquiries Jonathan R SmythPOP Biotechnologies, Inc.+1 315-220-0087jrsmyth@ us on social media:LinkedInError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma
VANCOUVER, BC / / May 26, 2025 / Onco-Innovations Limited (CBOE:ONCO) (Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Dalton Pharma Services ("Dalton") has commenced activities to manufacture material for preclinical testing of the Company's exclusively-licensed nanoparticle-formulated Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor technology. This important step marks the beginning of the transition from early-stage research and development to process scale-up and production for preclinical testing, enabling the generation of material needed for preclinical testing and planned future regulatory submissions which are key activities on the path toward clinical translation. The current phase of work includes process optimization and scale-up manufacturing aimed at producing 50 grams of Onco's proprietary PNKP inhibitor, known as A83B4C63. This material will be used in preclinical studies, including in-vitro and in-vivo testing, and is intended to support regulatory preparations for an Investigational New Drug (IND) submission in the United States, which the Company plans on making this year. Dalton, a leading Canadian contract development and manufacturing organization (CDMO), brings deep technical expertise and regulatory compliance capabilities to the project. In 2021, researchers from the University of Alberta published two peer-reviewed studies evaluating Onco-Innovations' nanoparticle-formulated PNKP inhibitor, A83B4C63, in preclinical models of colorectal cancer. The June study[1] demonstrated that treatment with the nanoparticle-encapsulated PNKP inhibitor significantly extended median survival in PTEN-deficient colorectal cancer-bearing mice to 60 days, compared to 23 days in untreated controls. The December study[2] found that combining the nanoparticle-formulated PNKP inhibitor with radiation therapy enhanced tumor growth delay in colorectal cancer models, without significant toxicity to healthy tissues. These findings support further development of the PNKP inhibitor as a targeted therapeutic approach in oncology. "This marks an important inflection point in our development roadmap, as manufacturing now begins to generate the material necessary to support future preclinical evaluation. We are now taking another tangible step toward translating a novel scientific approach towards potential therapeutic development, setting the stage for the next critical phases ahead," stated Thomas O'Shaughnessy, CEO of the Company. About Dalton Pharma ServicesDalton Pharma Services, established in 1986 and based in Toronto, Canada, is a Health Canada-approved and FDA-inspected GMP contract provider of integrated chemistry, drug development, and manufacturing services to the pharmaceutical and biotechnology industries. With over 35 years of experience, Dalton offers a comprehensive range of in-house services, including drug discovery, flow chemistry, formulation and process development, custom synthesis, cGMP sterile fill/finish, cGMP API manufacturing, and dosage form manufacturing. This integration at a single location enhances adaptability, flexibility, and cost-effectiveness, accelerating drug discovery and development programs. Dalton's commitment to quality, speed, and flexibility has been recognized with CMO Leadership Awards from Life Science Leader in 2016, 2017, and 2018 across categories such as Quality, Reliability, Capabilities, Expertise, Compatibility, and Development.[3] About Onco-Innovations LimitedOnco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED,"Thomas O'Shaughnessy"Chief Executive Officer For more information, please contact:Thomas O'ShaughnessyChief Executive OfficerTel: + 1 888 261 8055investors@ Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, including its PKNP Inhibitor Technology, the Company's ability to complete further preclinical or other research and development activities, and the Company's plans with respect to pursuing an IND, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies (including its PKNP Inhibitor Technology), the failure to submit an NDA or to pursue further regulatory or preclinical trials, the failure to receive regulatory approval in respect of its research and development activities, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. [1] Sadat et al. A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3′-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer. J Control Release. 2021 Jun 10;334:335-352. doi:10.1016/ [2] Sadat et al. Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage. Front Oncol. 2021 Dec 23;11:772920. doi: 10.3389/fonc.2021.772920 [3] SOURCE: Onco-Innovations Limited View the original press release on ACCESS Newswire
